오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - modafinil, quantity: 100 mg - tablet, uncoated - excipient ingredients: aluminium magnesium silicate; lactose monohydrate; croscarmellose sodium; povidone; maize starch; magnesium stearate; purified talc - modafinil is indicated:,? to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy;,? to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate;,? as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: polysorbate 80; macrogol 6000; magnesium stearate; sodium starch glycollate type b; microcrystalline cellulose; colloidal anhydrous silica; hypromellose; lactose monohydrate - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: polysorbate 80; sodium starch glycollate type b; hypromellose; magnesium stearate; macrogol 6000; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: polysorbate 80; magnesium stearate; hypromellose; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type b; macrogol 6000; lactose monohydrate - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; macrogol 6000; microcrystalline cellulose; sodium starch glycollate type b; hypromellose; magnesium stearate; polysorbate 80 - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type b; magnesium stearate; colloidal anhydrous silica; macrogol 6000; polysorbate 80; hypromellose - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type b; lactose monohydrate; hypromellose; colloidal anhydrous silica; microcrystalline cellulose; macrogol 6000; magnesium stearate; polysorbate 80 - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; magnesium stearate; povidone; titanium dioxide; hypromellose; macrogol 4000 - irbesartan is indicated for the following: for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan is indicated for the following: for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; povidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan is indicated for the following: for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.